非诺贝特治疗糖尿病视网膜病变的机制及其临床应用研究现状  

Mechanisms for the therapeutic effect of fenofibrate on diabetic retinopathy and its clinical application

作　　者：刘盈[1] 段细姝 徐积兄[1] 

机构地区：[1]南昌大学第一附属医院内分泌科,330006

出　　处：《中华眼底病杂志》2017年第2期206-209,共4页Chinese Journal of Ocular Fundus Diseases

基　　金：国家自然科学基金（81160105、81460018、81360017、81260336）

摘　　要：慢性炎症、氧化应激及视网膜神经节细胞凋亡在糖尿病视网膜病变（DR）发生发展过程中发挥重要作用.非诺贝特是过氧化物酶增生物激活受体α激动剂,除了降低血脂外,还能通过抗炎、抗氧化应激、抗凋亡以及抗新生血管等机制或途径干预DR发生发展过程.已有临床研究证实,非诺贝特具有缓解DR的效果.加强非诺贝特在糖尿病微血管病变治疗中的应用研究,进一步明确非诺贝特治疗DR的安全性及有效性对于DR治疗具有重要意义.Chronic inflammation,oxidative stress and retinal ganglion cell apoptosis play important roles in the development of diabetic retinopathy.Fenofibrate,a peroxisome proliferator-activated receptor α agonist,is used for dyslipidemia.In addition to its lipid-modulating effects,fenofibrate also has antiinflammatory,antioxidant,anti-apoptotic and anti-angiogenesis properties that may be useful to delay the progression of diabetic retinopathy.Some clinical studies have already confirmed that fenofibrate has therapeutic effect on diabetic retinopathy.Further studies the application of fenofibrate in the treatment of diabetic microangiopathy to clarify the safety and efficacy of fenofibrate is of great significance.

关 键 词：糖尿病视网膜病变/药物疗法 非诺贝特/治疗应用 综述 

分 类 号：R774.1[医药卫生—眼科]